NCT01093183 2023-09-13
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
University of Nebraska
Phase 1/2 Terminated
Clinical Trials
11 trialsNCT00460031 2020-07-24
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00348595 2019-04-12
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00942578 2018-10-11
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00988208 2018-04-04
Mainsail
Celgene
Phase 3 Completed
NCT00933426 2016-10-26
Lenalidomide and Paclitaxel in Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01378091 2016-05-09
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
Columbia University
Phase 1 Completed
NCT00654186 2014-03-28
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
Oncology Specialists, S.C.
Phase 2 Completed
NCT00939510 2013-01-31
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00179738 2005-11-23
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
Celgene
Phase 2 Terminated